Physician profile
Sara Chalifoux
NPI 1326451774
$12,868.79
in general payments reported to CMS, 2019-2025
35 companies · $1,329 in 2025
The $1,329 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $660 · 2021: $1,435 · 2022: $1,532 · 2023: $5,833 · 2024: $1,337 · 2025: $1,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,669 · Consulting Fee: $3,815 · Education: $14.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,669.12 |
| Consulting Fee | $3,815.00 |
| Education | $14.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $4,197.30 | 2019-2024 | Rebyota |
| Abbvie INC. | $2,627.82 | 2020-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $831.65 | 2022-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $780.64 | 2020-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $593.35 | 2024-2025 | Voquezna |
| Pfizer INC. | $484.34 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $357.25 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $345.09 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $335.53 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $277.47 | 2022-2024 | Dupixent |
| Janssen Scientific Affairs, LLC | $261.20 | 2022-2025 | Tremfya |
| Intercept Pharmaceuticals, INC. | $206.08 | 2020-2023 | Ocaliva |
| Redhill Biopharma INC. | $205.13 | 2021-2023 | Aemcolo, Talicia |
| Takeda Pharmaceuticals U.S.A., INC. | $162.00 | 2019-2021 | |
| Ardelyx, INC. | $147.78 | 2025 | Ibsrela |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $125.00 | 2025 | Airsupra |
| Braintree Laboratories, INC. | $108.24 | 2020-2024 | Suflave, Sutab |
| Lilly USA, LLC | $105.84 | 2024 | Omvoh |
| Celgene Corporation | $97.53 | 2022-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $88.35 | 2019-2020 | |
| Alfasigma USA, INC. | $81.60 | 2020 | |
| Fresenius Kabi USA, LLC | $51.04 | 2024-2025 | Idacio |
| Ironwood Pharmaceuticals, INC | $49.60 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $49.03 | 2021-2022 | |
| Shionogi INC | $47.42 | 2019-2020 | |
| Qol Medical, LLC | $46.70 | 2021-2022 | |
| Amgen INC. | $34.41 | 2022-2023 | Evenity, Prolia |
| Evoke Pharma, INC. | $31.92 | 2023 | Gimoti |
| Axonics, INC. | $26.64 | 2023 | Axonics |
| Scilex Pharmaceuticals INC. | $22.72 | 2023 | Ztlido |
| Guard Medical INC. | $21.81 | 2023 | Npseal (5), Npseal Large, Npseal Medium |
| Azurity Pharmaceuticals, INC. | $20.76 | 2023 | Edarbi |
| Jazz Pharmaceuticals INC. | $18.67 | 2023 | |
| Celltrion USA INC. | $15.29 | 2024 | Vegzelma |
| Novo Nordisk INC | $13.59 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Chalifoux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.